RBC Capital Reiterates Their Hold Rating on Chemed

By Jason Carr

RBC Capital analyst Frank Morgan reiterated a Hold rating on Chemed (NYSE: CHE) yesterday and set a price target of $209. The company’s shares opened today at $199.98.

According to TipRanks.com, Morgan is a 5-star analyst with an average return of 13.7% and a 65.5% success rate. Morgan covers the Services sector, focusing on stocks such as Fresenius Medical Care Corp, Quest Diagnostics Inc, and Team Health Holdings.

Chemed has an analyst consensus of Moderate Buy, with a price target consensus of $214.50.

Chemed’s market cap is currently $3.2B and has a P/E ratio of 50.12. The company has a book value ratio of 6.3900.

Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2017, Donald Saunders, a Director at CHE bought 94 shares for a total of $19,325.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments.